Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer.
J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d.
J Med Chem. 2008.
PMID: 18754654
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P.
Raynaud FI, et al. Among authors: lensun l.
Mol Cancer Ther. 2009 Jul;8(7):1725-38. doi: 10.1158/1535-7163.MCT-08-1200. Epub 2009 Jul 7.
Mol Cancer Ther. 2009.
PMID: 19584227
Free PMC article.
Item in Clipboard
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.
Wallin JJ, et al. Among authors: lensun l.
Mol Cancer Ther. 2011 Dec;10(12):2426-36. doi: 10.1158/1535-7163.MCT-11-0446. Epub 2011 Oct 13.
Mol Cancer Ther. 2011.
PMID: 21998291
Item in Clipboard
Functional characterization of a novel somatic oncogenic mutation of PIK3CB.
Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ.
Whale AD, et al. Among authors: lensun l.
Signal Transduct Target Ther. 2017 Dec 22;2:17063. doi: 10.1038/sigtrans.2017.63. eCollection 2017.
Signal Transduct Target Ther. 2017.
PMID: 29279775
Free PMC article.
Item in Clipboard
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.
Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA.
Nastoupil LJ, et al. Among authors: lensun l.
Leuk Lymphoma. 2021 Dec;62(14):3452-3462. doi: 10.1080/10428194.2021.1957874. Epub 2021 Aug 9.
Leuk Lymphoma. 2021.
PMID: 34365878
Clinical Trial.
Item in Clipboard
Time-resolved evanescent wave-induced fluorescence anisotropy for the determination of molecular conformational changes of proteins at an interface.
Gee ML, Lensun L, Smith TA, Scholes CA.
Gee ML, et al. Among authors: lensun l.
Eur Biophys J. 2004 Apr;33(2):130-9. doi: 10.1007/s00249-003-0360-5. Epub 2003 Oct 28.
Eur Biophys J. 2004.
PMID: 14586518
Item in Clipboard
Cite
Cite